----

----

|  ATLAS THERAPEUTICS CORPORATION                         |
|--------------------------------------------------------------|
|  (Exact name of registrant as specified in its charter) |

| Nevada                                                         |   | 20-8758875                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or other jurisdiction of incorporation or organization) |   | (I.R.S. Employer Identification No.) |

| 4640 Admiralty Way, Suite 500Marina Del Rey, CA 90292(Address of Principal Executive Offices) (310) 496-5727(Registrant’s telephone number, including area code) |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |
|--------|

| o  Large accelerated filer | o  Accelerated filer         |
|--------------------------------------|----------------------------------------|
|                                 |                                   |
| o  Non-accelerated filer   | x  Smaller reporting company |

----

| INDEX                                                                                                                                                                                          | Page     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
|                                                                                                                                                                                           |     |
| PART 1-FINANCIAL INFORMATION                                                                                                                                                                   | 2        |
|                                                                                                                                                                                           |     |
| Item 1.  Financial Statements                                                                                                                                                        | 2        |
|                                                                                                                                                                                           |     |
| Consolidated Balance Sheets as of March 31, 2011 (unaudited) and December 31, 2010                                                                                                             | 2        |
|                                                                                                                                                                                           |     |
| Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2011 and 2010 and the period from inception (April 11, 2007) to March 31, 2011                          | 3        |
|                                                                                                                                                                                           |     |
| Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2011 (unaudited) and for the period from inception (April 11, 2007) to December 31, 2010 | 4        |
|                                                                                                                                                                                           |     |
| Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2011 and 2010 and the period from inception (April 11, 2007) to March 31, 2011                          | 5        |
|                                                                                                                                                                                           |     |
| Notes to Consolidated Financial Statements                                                                                                                                                     | 7        |
|                                                                                                                                                                                           |     |
| Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations                                                                                 | 12       |
|                                                                                                                                                                                           |     |
| Item 3.  Quantitative and Qualitative Disclosures about Market Risk                                                                                                                  | 14       |
|                                                                                                                                                                                           |     |
| Item 4.  Controls and Procedures                                                                                                                                                     | 14       |
|                                                                                                                                                                                           |     |
| PART II-OTHER INFORMATION                                                                                                                                                                      |     |
|                                                                                                                                                                                           |     |
| Item 1.  Legal Proceedings                                                                                                                                                           | 15       |
|                                                                                                                                                                                           |     |
| Item 1A.  Risk Factors                                                                                                                                                               | 15       |
|                                                                                                                                                                                           |     |
| Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds                                                                                                                 | 15       |
|                                                                                                                                                                                           |     |
| Item 3.  Defaults Upon Senior Securities                                                                                                                                             | 15       |
|                                                                                                                                                                                           |     |
| Item 4.  [Removed and Reserved]                                                                                                                                                      | 15       |
|                                                                                                                                                                                           |     |
| Item 5.  Other Information                                                                                                                                                           | 15       |
|                                                                                                                                                                                           |     |
| Item 6.  Exhibits                                                                                                                                                                    | 15       |
|                                                                                                                                                                                           |     |
| SIGNATURES                                                                                                                                                                                     |  16 |

----

| ATLAS THERAPEUTICS CORPORATION AND SUBSIDIARY                                                                                                                                               |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| (a development stage company)                                                                                                                                                               |   |
| CONSOLIDATED BALANCE SHEETS                                                                                                                                                                 |   |
|                                                                                                                                                                                        |   |
|                                                                                                                                                                                        |   | (Unaudited) |   |   | December 31, 2010 |   |
|                                                                                                                                                                                        |   | March 31, 2011 |   |
| ASSETS                                                                                                                                                                                      |   |   |   |   |   |   |
| Current assets                                                                                                                                                                              |   |   |   |   |   |   |
| Cash                                                                                                                                                                                        |   | $ | 599,357 |   |   | $ | - |   |
| Prepaid expenses and other current assets                                                                                                                                                   |   |   | 209,842 |   |   |   | - |   |
|                                                                                                                                                                                        |   |   | 809,199 |   |   |   | - |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Fixed assets, net of accumulated depreciation of $26                                                                                                                                        |   |   | 1,543 |   |   |   | - |   |
| Intellectual property                                                                                                                                                                       |   |   | 4,662,000 |   |   |   | - |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total assets                                                                                                                                                                                |   | $ | 5,472,742 |   |   | $ | - |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Current liabilities                                                                                                                                                                         |   |   |   |   |   |   |   |   |
| Accounts payable and accrued expenses                                                                                                                                                       |   | $ | 13,600 |   |   | $ | 535 |   |
| Note payable to related party for acquisition of intellectual property                                                                                                            |   |   | 700,000 |   |   |   | - |   |
| Accrued interest                                                                                                                                                                            |   |   | 1,933 |   |   |   | - |   |
| Accounts payable related party                                                                                                                                                              |   |   | 45,911 |   |   |   | 45,911 |   |
| Note payable - insurance financing                                                                                                                                                          |   |   | 32,013 |   |   |   | - |   |
| Note payable                                                                                                                                                                                |   |   | 7,500 |   |   |   | 7,500 |   |
| Total current liabilities                                                                                                                                                                   |   |   | 800,957 |   |   |   | 53,946 |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Derivatives liability                                                                                                                                                                       |   |   | 2,810,000 |   |   |   | - |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total liabilities                                                                                                                                                                           |   |   | 3,610,957 |   |   |   | 53,946 |   |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Stockholders' equity                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Preferred stock, $.001 par value; 25,000,000 shares authorized; no shares issued and outstanding                                                                                            |   |   | - |   |   |   | - |   |
| Common stock, $.001 par value, 300,000,000 shares authorized; 60,790,666 shares issued and outstanding at March 31, 2011 and; 49,000,000 shares issued and outstanding at December 31, 2010 |   |   | 60,791 |   |   |   | 49,000 |   |
| Additional paid-in capital                                                                                                                                                                  |   |   | 4,108,465 |   |   |   | 31,000 |   |
| Deficit accumulated during development stage                                                                                                                                                |   |   | (2,307,471 | ) |   |   | (133,946 | ) |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total stockholders' equity                                                                                                                                                                  |   |   | 1,861,785 |   |   |   | (53,946 | ) |
|                                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders' equity                                                                                                                                                  |   | $ | 5,472,742 |   |   | $ | - |   |

----

| ATLAS THERAPEUTICS CORPORATION AND SUBSIDIARY                            |   |
|--------------------------------------------------------------------------|--------|
| (a development stage company)                                            |   |
| CONSOLIDATED STATEMENTS OF OPERATIONS                                    |   |
| (Unaudited)                                                              |   |
|                                                                     |   |   |   |   |   |   |   | April 11, 2007 |   |
|                                                                     |   | Three Months Ended March 31, |   |   | (date of inception) to |   |
|                                                                     |   | 2011 |   |   | 2010 |   |   | March 31, 2011 |   |
|                                                                     |   |   |   |   |   |   |   |   |   |
| Revenue                                                                  |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| General and administrative expenses                                      |   |   | 1,711,266 |   |   |   | 4,776 |   |   |   | 1,857,482 |   |
| Loss from operations                                                     |   |   | (1,711,266 | ) |   |   | (4,776 | ) |   |   | (1,857,482 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |
| Other Income                                                             |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |
| Interest expense                                                         |   |   | (2,259 | ) |   |   | - |   |   |   | (2,489 | ) |
| Increase in fair value of warrants                                       |   |   | (460,000 | ) |   |   | - |   |   |   | (460,000 | ) |
| Gain on forgiveness of debt                                              |   |   | - |   |   |   | 12,500 |   |   |   | 12,500 |   |
|                                                                     |   |   | (462,259 | ) |   |   | 12,500 |   |   |   | (449,989 | ) |
| Net (loss) income                                                        |   | $ | (2,173,525 | ) |   | $ | 7,724 |   |   | $ | (2,307,471 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average number of common shares outstanding, basic and diluted  |   |   | 53,454,523 |   |   |   | 49,000,000 |   |   |   |   |   |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |
| Basic and diluted net loss per share attributable to common stockholders |   | $ | (0.04 | ) |   | $ | 0.00 |   |   |   |   |   |

----

| ATLAS THERAPEUTICS CORPORATION AND SUBSIDIARY                                                                              |            |
|----------------------------------------------------------------------------------------------------------------------------|-----------------|
| (a development stage company)                                                                                              |            |
| CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)                                                      |            |
| For the period from April 11, 2007 (date of inception) to                                                                  |            |
| March 31, 2011                                                                                                             |            |
|                                                                                                                       |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | Deficit accumulated during development stage |   |   |   |   |
|                                                                                                                       | Preferred Stock |   |   | Common Stock |   |   |   |   |   | Total stockholders' equity |   |
|                                                                                                                       | Shares          |   |   | Amount $.001 par |   |   | Shares |   |   | Amount $.001 par |   |   | Additional paid-in capital |   |
| Balance at April 11, 2007                                                                                                  |            |   | - |   |   | $ | - |   |   |   | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |   | $ | - |   |
| Common stock issued for cash at $0.0002 per share                                                                          |            |   |   |   |   |   |   |   |   |   | 28,000,000 |   |   |   | 28,000 |   |   |   | (23,000 | ) |   |   |   |   |   |   | 5,000 |   |
| Common stock issued for cash at $0.004 per share                                                                           |            |   |   |   |   |   |   |   |   |   | 21,000,000 |   |   |   | 21,000 |   |   |   | 54,000 |   |   |   |   |   |   |   | 75,000 |   |
| Net loss                                                                                                                   |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (60,185 | ) |   |   | (60,185 | ) |
| Balance at December 31, 2007                                                                                               |            |   | - |   |   |   | - |   |   |   | 49,000,000 |   |   |   | 49,000 |   |   |   | 31,000 |   |   |   | (60,185 | ) |   |   | 19,815 |   |
| Net loss                                                                                                                   |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (17,928 | ) |   |   | (17,928 | ) |
| Balance at December 31, 2008                                                                                               |            |   | - |   |   |   | - |   |   |   | 49,000,000 |   |   |   | 49,000 |   |   |   | 31,000 |   |   |   | (78,113 | ) |   |   | 1,887 |   |
| Net loss                                                                                                                   |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (39,308 | ) |   |   | (39,308 | ) |
| Balance at December 31, 2009                                                                                               |            |   | - |   |   |   | - |   |   |   | 49,000,000 |   |   |   | 49,000 |   |   |   | 31,000 |   |   |   | (117,421 | ) |   |   | (37,421 | ) |
| Net loss                                                                                                                   |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (16,525 | ) |   |   | (16,525 | ) |
| Balance at December 31, 2010                                                                                               |            |   | - |   |   |   | - |   |   |   | 49,000,000 |   |   |   | 49,000 |   |   |   | 31,000 |   |   |   | (133,946 | ) |   |   | (53,946 | ) |
| Proceeds from private placement of restricted common stock                                                                 |            |   |   |   |   |   |   |   |   |   | 4,757,520 |   |   |   | 4,758 |   |   |   | 1,422,498 |   |   |   |   |   |   |   | 1,427,256 |   |
| Conversion of stockholder loan into common stock                                                                           |            |   |   |   |   |   |   |   |   |   | 9,146 |   |   |   | 9 |   |   |   | 2,735 |   |   |   |   |   |   |   | 2,744 |   |
| Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property |            |   |   |   |   |   |   |   |   |   | 7,024,000 |   |   |   | 7,024 |   |   |   | 3,504,976 |   |   |   |   |   |   |   | 3,512,000 |   |
| Offering Costs                                                                                                             |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (25,000 | ) |   |   |   |   |   |   | (25,000 | ) |
| Conversion of stockholder loan into capital - no shares issued                                                             |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 22,256 |   |   |   |   |   |   |   | 22,256 |   |
| Fair value of warrants issued to private placement investors                                                               |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (2,350,000 | ) |   |   |   |   |   |   | (2,350,000 | ) |
|                                                                                                                       |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Fair value of shares transferred from existing stockholder to the CEO in connection with employment agreement              |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | 1,500,000 |   |   |   |   |   |   |   | 1,500,000 |   |
| Net loss                                                                                                                   |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (2,173,525 | ) |   |   | (2,173,525 | ) |
| Balance at                                                                                                                 |            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| March 31, 2011                                                                                                             |            |   | - |   |   | $ | - |   |   |   | 60,790,666 |   |   | $ | 60,791 |   |   | $ | 4,108,465 |   |   | $ | (2,307,471 | ) |   | $ | 1,861,785 |   |

----

| ATLAS THERAPEUTICS CORPORATION AND SUBSIDIARY                               |   |
|-----------------------------------------------------------------------------|--------|
| (a development stage company)                                               |   |
| CONSOLIDATED STATEMENTS OF CASH FLOWS                                       |   |
| (Unaudited)                                                                 |   |
|                                                                        |   |   |   |   |   |   |   |   |   |
|                                                                        |   |   |   |   |   |   |   | April 11, 2007 |   |
|                                                                        |   |   |   |   |   |   |   | (date of |   |
|                                                                        |   |   |   |   |   |   |   | inception) to |   |
|                                                                        |   | Three Months Ended March 31, |   |   | March 31, |   |
|                                                                        |   | 2011 |   |   | 2010 |   |   | 2011 |   |
| Cash Flows from Operating Activities                                        |   |   |   |   |   |   |   |   |   |
| Net loss                                                                    |   | $ | (2,173,525 | ) |   | $ | 7,724 |   |   | $ | (2,307,471 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |   |   |   |   |   |   |   |   |   |   |   |
| Depreciation                                                                |   |   | 26 |   |   |   | - |   |   |   | 26 |   |
| Stock based compensation                                                    |   |   | 1,500,000 |   |   |   | - |   |   |   | 1,500,000 |   |
| Gain from forgiveness of debt                                               |   |   | - |   |   |   | 12,500 |   |   |   | - |   |
| Increase in fair value of warrants                                          |   |   | 460,000 |   |   |   | - |   |   |   | 460,000 |   |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Changes in operating assets and liabilities:                                |   |   |   |   |   |   |   |   |   |   |   |   |
| (Increase) in prepaid expenses and other current assets                     |   |   | (167,342 | ) |   |   | - |   |   |   | (167,342 | ) |
| Increase in accounts payable and accrued expenses                           |   |   | 14,998 |   |   |   | (24,850 | ) |   |   | 15,533 |   |
| Net cash used in operating activities                                       |   |   | (365,843 | ) |   |   | (4,626 | ) |   |   | (499,254 | ) |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash Flows from Investing Activities:                                       |   |   |   |   |   |   |   |   |   |   |   |   |
| Acquisition of intellectual property                                        |   |   | (450,000 | ) |   |   | - |   |   |   | (450,000 | ) |
| Acquisition of fixed assets                                                 |   |   | (1,569 | ) |   |   | - |   |   |   | (1,569 | ) |
| Net cash used in investing activities                                       |   |   | (451,569 | ) |   |   | - |   |   |   | (451,569 | ) |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash Flows from Financing Activities                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Advances from related parties                                               |   |   | - |   |   |   | 5,000 |   |   |   | 53,411 |   |
| Repayment of insurance financing note                                       |   |   | (10,487 | ) |   |   | - |   |   |   | (10,487 | ) |
| Proceeds from issuance of stock to initial stockholders                     |   |   | - |   |   |   | - |   |   |   | 80,000 |   |
| Proceeds from private placement of common stock                             |   |   | 1,427,256 |   |   |   | - |   |   |   | 1,427,256 |   |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Net cash provided by financing activities                                   |   |   | 1,416,769 |   |   |   | 5,000 |   |   |   | 1,550,180 |   |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Net increase in cash                                                        |   |   | 599,357 |   |   |   | 374 |   |   |   | 599,357 |   |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash at beginning of the period                                             |   |   | - |   |   |   | 145 |   |   |   | - |   |
|                                                                        |   |   |   |   |   |   |   |   |   |   |   |   |
| Cash at end of the period                                                   |   | $ | 599,357 |   |   | $ | 519 |   |   | $ | 599,357 |   |

----

| ATLAS THERAPEUTICS CORPORATION AND SUBSIDIARY                      |   |
|--------------------------------------------------------------------|--------|
| (a development stage company)                                      |   |
| CONSOLIDATED STATEMENTS OF CASH FLOW                               |   |
| (Continued)                                                        |   |
|                                                               |   |   |   |   |   |   |   |   |   |
|                                                               |   |   |   |   |   |   |   |   |   |
|                                                               |   |   |   |   |   |   | April 11, 2007 |   |
|                                                               |   |   |   |   |   |   |   | (date of |   |
|                                                               |   |   |   |   |   |   |   | inception) to |   |
|                                                               |   | Three Months Ended March 31, |   |   | March 31, |   |
|                                                               |   | 2011 |   |   | 2010 |   |   | 2011 |   |
|                                                               |   |   |   |   |   |   |   |   |   |
| Supplemental Disclosure of cash flow information:                  |   |   |   |   |   |   |   |   |   |
| Cash paid for franchise taxes                                      |   | $ | 800 |   |   | $ | - |   |   | $ | 800 |   |
| Cash paid for interest                                             |   | $ | - |   |   | $ | - |   |   | $ | - |   |
|                                                               |   |   |   |   |   |   |   |   |   |   |   |   |
| Supplemental Disclosure of Non-cash transactions:                  |   |   |   |   |   |   |   |
| Offering costs paid by stockholder                                 |   | $ | 25,000 |   |   | $ | - |   |   | $ | 25,000 |   |
| Conversion of stockholder loan into common stock                   |   | $ | 2,744 |   |   | $ | - |   |   | $ | 2,744 |   |
| Conversion of stockholder loan into capital - no shares issued     |   | $ | 22,256 |   |   | $ | - |   |   | $ | 22,256 |   |
| Note payable - insurance financing                                 |   | $ | 42,500 |   |   | $ | - |   |   | $ | 42,500 |   |
| Note payable to related party for purchase of intellectual propery |   | $ |  700,000 |   |   | $ | - |   |   | $ |  700,000 |   |

----

----

|                      |   | For the Three Months Ended March 31, |              |
|---------------------------|--------|--------------------------------------|-------------------|
|                      |   | 2011                                 |              |   | 2010 |   |
| (Loss) Income (Numerator) |   | $                                    |  (2,173,525) |   |   | $ |  7,724 |   |
| Shares (Denominator)      |   |                                 |  53,454,523  |   |   |   |  49,000,000 |   |
| Per share amount          |   | $                                    |  (0.04)      |   |   | $ |  0.00 |   |

----

----

----

----

| ·   | Established our website which is ready to go live and commence order taking in June 2011. |
|--------------------|-------------------------------------------------------------------------------------------|

| ·   | Purchased products ready and available for resale shipping. |
|--------------------|-------------------------------------------------------------|

| ·   | Entered into fulfillment and credit card processing agreements. |
|--------------------|-----------------------------------------------------------------|

| ·   | Entered into sales agency agreements. |
|--------------------|---------------------------------------|

| ·   | Entered into consulting agreements. |
|--------------------|-------------------------------------|

----

| Office equipment | 5 years |
|------------------|---------|

----

----

| No.  | Description of Exhibit                                                                                                               |
|------|--------------------------------------------------------------------------------------------------------------------------------------|
| 31.1 | Certification of Principal Executive Officer/Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   |
| 32.1 | Certification of Principal Executive Officer / Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 0f 2002 |

----

|                          | ATLAS THERAPEUTICS CORPORATION |
|-------------------------------|--------------------------------|
|                          |                           |
| Date:  May 16, 2011 | By: /s/ J.B. Bernstein    |
|                          | J.B. Bernstein                 |
|                          | Chief Executive Officer        |

| Signature          |   | Title(s)                                                      | Date         |
|--------------------|--------|---------------------------------------------------------------|--------------|
|               |   |                                                          |         |
| /s/ J.B. Bernstein |   | Chief Executive Officer and Director                          | May 16, 2011 |
| J.B. Bernstein     |   | (Principal Executive Officer and Principal Financial Officer) |         |
|               |   |                                                          |         |

----